$3.46 Billion is the total value of BB BIOTECH AG's 32 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IONS | Buy | Ionis Pharmaceuticals Inc. | $361,126,000 | -3.8% | 8,666,334 | +1.8% | 10.43% | +0.5% |
| NBIX | Sell | Neurocrine Biosciences Inc. | $325,936,000 | +15.5% | 3,317,753 | -2.5% | 9.41% | +20.7% |
| CELG | Celgene Corp | $264,016,000 | -11.0% | 3,324,298 | 0.0% | 7.62% | -7.0% | |
| INCY | Buy | Incyte Corp. | $251,808,000 | -18.3% | 3,758,322 | +1.6% | 7.27% | -14.6% |
| VRTX | Sell | Vertex Pharmaceuticals Inc. | $238,020,000 | -1.0% | 1,400,445 | -5.1% | 6.87% | +3.4% |
| AGIO | Sell | Agios Pharmaceuticals Inc. | $185,132,000 | -10.7% | 2,197,931 | -13.3% | 5.34% | -6.7% |
| RDUS | Buy | Radius Health Inc. | $182,741,000 | -13.1% | 6,200,913 | +5.9% | 5.28% | -9.3% |
| GILD | Sell | Gilead Sciences Inc. | $168,216,000 | -16.6% | 2,374,596 | -11.2% | 4.86% | -12.8% |
| SAGE | Buy | Sage Therapeutics Inc. | $167,702,000 | +3.9% | 1,071,373 | +6.9% | 4.84% | +8.5% |
| ALXN | Sell | Alexion Pharmaceuticals Inc. | $166,911,000 | +7.4% | 1,344,428 | -3.6% | 4.82% | +12.2% |
| HALO | Sell | Halozyme Therapeutics Inc. | $139,141,000 | -16.6% | 8,247,860 | -3.2% | 4.02% | -12.9% |
| ESPR | Buy | Esperion Therapeutics Inc. | $124,740,000 | -28.5% | 3,182,964 | +31.9% | 3.60% | -25.3% |
| ALNY | Buy | Alnylam Pharmaceuticals, Inc. | $112,332,000 | -6.7% | 1,140,538 | +12.8% | 3.24% | -2.6% |
| TSRO | Buy | Tesaro Inc. | $107,920,000 | +15.9% | 2,426,802 | +48.9% | 3.12% | +21.1% |
| REGN | Sell | Regeneron Pharmaceuticals Inc. | $93,147,000 | -3.4% | 270,000 | -3.6% | 2.69% | +0.9% |
| MYOV | Myovant Sciences Ltd. | $80,225,000 | +7.5% | 3,507,882 | 0.0% | 2.32% | +12.3% | |
| AKCA | Buy | Akcea Therapeutics, Inc. | $58,897,000 | -3.8% | 2,484,071 | +4.0% | 1.70% | +0.6% |
| MGNX | Buy | MacroGenics Inc. | $54,938,000 | -16.0% | 2,660,412 | +2.3% | 1.59% | -12.3% |
| VYGR | Buy | Voyager Therapeutics Inc. | $49,488,000 | +32.2% | 2,532,641 | +27.1% | 1.43% | +38.1% |
| ICPT | Intercept Pharmaceuticals Inc. | $45,791,000 | +36.4% | 545,719 | 0.0% | 1.32% | +42.5% | |
| WVE | Buy | Wave Life Sciences Ltd. | $43,524,000 | +21.1% | 1,137,885 | +27.0% | 1.26% | +26.6% |
| ITCI | Intra-Cellular Therapies Inc. | $38,874,000 | -16.1% | 2,200,000 | 0.0% | 1.12% | -12.3% | |
| ARGX | Buy | Argenx SEsponsored adr | $37,208,000 | +16.6% | 449,049 | +13.2% | 1.07% | +21.8% |
| ALDR | Alder Biopharmaceuticals Inc. | $35,803,000 | +24.4% | 2,266,008 | 0.0% | 1.03% | +30.1% | |
| NKTR | New | Nektar Therapeutics | $25,636,000 | – | 525,000 | +100.0% | 0.74% | – |
| MYOK | New | Myokardia Inc. | $23,832,000 | – | 480,000 | +100.0% | 0.69% | – |
| EXEL | New | Exelixis Inc. | $22,811,000 | – | 1,060,000 | +100.0% | 0.66% | – |
| FPRX | Five Prime Therapeutics Inc. | $15,454,000 | -8.0% | 977,500 | 0.0% | 0.45% | -3.9% | |
| GTHX | New | G1 Therapeutics Inc. | $15,324,000 | – | 352,607 | +100.0% | 0.44% | – |
| CDTX | Cidara Therapeutics Inc. | $11,935,000 | +30.0% | 2,295,272 | 0.0% | 0.34% | +35.8% | |
| NVAX | Novavax Inc. | $11,162,000 | -36.2% | 8,330,000 | 0.0% | 0.32% | -33.3% | |
| ACHN | Achillion Pharmaceuticals Inc. | $3,621,000 | -23.7% | 1,279,340 | 0.0% | 0.10% | -19.8% | |
| PRTA | Exit | Prothena Corp. PLC | $0 | – | -400,000 | -100.0% | -0.41% | – |
| AVXS | Exit | AveXis, Inc. | $0 | – | -402,800 | -100.0% | -1.38% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N V #1
- Biotech Invest N V #2
- Biotech Target N V #3
- Biotech Growth N V #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.